Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.32 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466116 | 1.00 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| SCHEMBL3466270 | 1.00 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| Potassium Ion SCHEMBL3467421 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| Zinc Ion SCHEMBL3466723 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| SCHEMBL3466753 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| Lithium Ion SCHEMBL3466824 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| SCHEMBL3466662 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| SCHEMBL3466066 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| SCHEMBL3467701 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 | |
| Zinc Ion SCHEMBL3466748 | 0.95 | POLB (0.45) | POLBHPGDL3MBTL1HSD11B1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966944-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10751307-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS LLC (US) | 2020-08-25 | — | — | US | disclosed |
| EP-2396002-B1 | (2.2.2) BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200215008-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20180200211-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9943493-B2 | [2.2.2] bicyclic derivatives and methods of use | ASE PHARMACEUTICALS, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170000750-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS, LLC | 2017-01-05 | — | — | US | disclosed |
| WO-2010071872-A2 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | ASE PHARMACEUTICALS, LLC (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215008-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GOT2, FABP1 | POLB 2472/4885HPGD 1992/4885L3MBTL1 3828/4885 |
| US-10751307-B2 | [2.2.2] bicyclic derivatives and methods of use | OAT, GABRA2, GOT2 | POLB 1987/4885HPGD 2166/4885L3MBTL1 3810/4885 |
| US-10966944-B2 | [2.2.2] bicyclic derivatives and methods of use | OAT, GOT2, FABP1 | POLB 2472/4885HPGD 1992/4885L3MBTL1 3828/4885 |
| US-20170000750-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GABRA2, GOT2 | POLB 1987/4885HPGD 2166/4885L3MBTL1 3810/4885 |
| US-20180200211-A1 | [2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE | OAT, GABRA2, GOT2 | POLB 1987/4885HPGD 2166/4885L3MBTL1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.